The White Ribbon Project

Everyday more news about lung cancer is coming out. This is exciting!

Roche announced that its investigational drug divarasib outperformed existing approved therapies in a late-stage trial for people with advanced, previously treated lung cancer with improvements in overall survival and progression-free survival compared with approved KRAS G12C therapies.

That matters.

Every new advance, every successful trial, every new option brings more hope to people and families facing lung cancer.

This is what progress looks like: research moving forward, treatment options expanding, and lung cancer finally receiving more of the urgency and innovation it has always deserved.

We are grateful to see more efforts in lung cancer research coming to life.

More options mean more hope.
More research means more time, which means everything.

Anyone with lungs can get lung cancer, and no one ever deserves it. 🤍✨🫁

https://www.wsj.com/health/pharma/roche-lung-cancer-drug-candidate-beats-existing-therapies-in-late-stage-trial-548e7ca0

Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial Experimental drug, divarasib, showed meaningful improvements in both patients’ overall survival and the time they survived without the disease worsening.